case_images: PMC11405151_01
case_images: Comparison between the basal FDG-PET and the FDG-PET performed after two weeks of imatinib therapy. (A) High tracker uptake in liver metastasis at baseline. (B) Complete metabolic response in liver metastasis after two weeks of imatinib therapy. (C) High tracker uptake in peritoneal metastasis at baseline. (D) Near-complete metabolic response in peritoneal metastasis after two weeks of imatinib therapy.
case_images: fonc-14-1450889-g001.jpg
case_images: PMC11405151_01_fonc-14-1450889-g001.jpg
case_images: f1
case_images: PET examination, performed two weeks after treatment start, demonstrated near-complete metabolic response with absence of FDG uptake in the known sites of disease ( Figure 1 ).
case_images: Pelvic MRI showing male genital system metastases. (A) The red arrow indicates the lesion in the corpus spongiosum. (B) The red arrow indicates the lesion in the corpus cavernosum.
case_images: fonc-14-1450889-g002.jpg
case_images: PMC11405151_01_fonc-14-1450889-g002.jpg
case_images: f2
case_images: Cardiac MRI showing myocardial metastases. (A) The red arrow shows the lesion in the left ventricle. (B) The red arrow shows the lesion in the right ventricle.
case_images: fonc-14-1450889-g003.jpg
case_images: PMC11405151_01_fonc-14-1450889-g003.jpg
case_images: f3
case_images: Cardiac MRI confirmed a mass near the left ventricular apex (4 cm), a mass in the right ventricle under the tricuspid valve (5 cm) and another mass in the right atrium near the atrial septum (3 cm), with imaging strongly suggestive for GIST metastases ( Figure 3 ).
case_images: Schematic representation of the patient's treatment history.
case_images: fonc-14-1450889-g004.jpg
case_images: PMC11405151_01_fonc-14-1450889-g004.jpg
case_images: f4